Device Trial Radar · NCT05870566
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Nov 20, 2023
Primary completion
Sep 30, 2027
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Claus CursiefenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Uniklinik Köln, Zentrum für Klinische Studien; Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik; German Federal Ministry of Education and Research
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.
Conditions
- Corneal Transplantation
Interventions
Corneal CrosslinkingDevice
Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized "accelerated CXL protocol" (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04\_0 Page 45-46)
Primary outcomes
What the sponsor says the trial is designed to measure.
- First episode of endothelial graft rejectionTime frame: within 24 months after transplantation
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin, Klinik für Augenheilkunde
Berlin, Germany · Recruiting
Universitätsklinikum Freiburg, Klinik für Augenheilkunde
Freiburg im Breisgau, Germany · Recruiting
Klinik und Poliklinik für Augenheilkunde - Universitätsmedizin Rostock
Rostock, Germany · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.